Tirzepatide
What to know about Tirzepatide
Tirzepatide acts on two hormone signals, GIP and GLP-1, involved in appetite and blood-sugar control. Approved products have been studied in large human trials.
- How it may work
- It activates GIP and GLP-1 receptors, influencing glucose-dependent insulin release, glucagon, gastric emptying, and appetite-related signalling.
- What research found
- SURMOUNT-1 randomized 2,539 adults for 72 weeks and reported dose-dependent average weight reductions that exceeded placebo. Separate glucose-control trials provide additional evidence.
- What is not settled
- Stomach and gut side effects are common. Approved product instructions explain who should not use them, warning signs, dose changes and medicines that need extra care.
- Research and product status
- Tirzepatide has licensed U.S. products for specific uses. Compounded or research-labelled material is not the same product as a licensed formulation.
Research reference
- Research amount range
- 2.5–15 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Reported timing context
- Once weekly on the same day; time of day is flexible.
- What people report
- Appetite changes are often noticed early; the amount is stepped up gradually to limit gastrointestinal effects.
- Model accumulation timescale
- ~25.0 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- titrated over months
- Reported break context
- n/a — titrated, not cycled Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- SURMOUNT-1 measured weight change at 72 weeks, including 20 weeks of gradual dose increases. Its result describes months of treatment, not a promise about the first dose or first month.
- When to assess
- The first weeks focus on gradual dose increases and checking side effects. Agree a goal and check-in plan with your provider. Judge progress after enough time at a regular dose you can tolerate, using the current product instructions.
- Conditions and limitations
- The pivotal study included lifestyle support. No special time of day or fasting condition was required, but the formulation, gradual escalation, and studied population matter.
- When to stop
- Agree when to stop with your prescriber, using the current product instructions. Get prompt advice for severe side effects, effects that do not settle, or listed warning signs. Slow early weight loss is not a reason to raise the dose faster.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Tirzepatide alongside other compounds or medicines.
Key properties
- Formula
- C225H348N48O68
- Mol. weight
- 4,813.53 Da
- CAS
- 2023788-19-2
- PubChem CID
- 166567236
External references
Vial arithmetic
Published research contexts for Tirzepatide describe 2.5–15 mg per administration. Descriptive only, not a recommendation.
Research schedule reference
Reported schedule context for Tirzepatide; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Starting step to limit gastrointestinal effects. | 2.5 mg | Once weekly | SubQ |
| Weeks 5–8 | 5 mg | Once weekly | SubQ |
| Weeks 9–12 | 7.5 mg | Once weekly | SubQ |
| Weeks 13–16 | 10 mg | Once weekly | SubQ |
| Week 17+Step up in 2.5 mg increments no sooner than every 4 weeks. | 12.5–15 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- SURMOUNT-1 (Jastreboff et al., NEJM 2022)Weekly tirzepatide 5–15 mg in obesity research.